Skip to main content
. Author manuscript; available in PMC: 2022 Mar 29.
Published in final edited form as: Biomed Pharmacother. 2020 Aug 21;130:110596. doi: 10.1016/j.biopha.2020.110596

Fig. 3.

Fig. 3.

Change from baseline to final follow-up in A) left ventricular ejection fraction (EF), B) estimated glomerular filtration rate (eGFR), and C) N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. (*p < 0.05, ** p < 0.001 vs. baseline), ARNI angiotensin receptor neprilysin inhibitor; OMT standard optimal medical treatment.